Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi

Sexually Transmitted Infections

Volumn 86, Issue 5, 2010, Pages 345-352

  Phiri, Sam ^a,b   Hoffman, Irving F ^c   Weiss, Helen A ^b   Martinson, Francis ^d   Nyirenda, Naomi ^d   Kamwendo, Debbie ^d   Fiscus, Susan A ^c   Chen, Cheng Yen ^e   Miller, William C ^c   Van Der Hoeven, Len ^f   Chilongozi, David ^d   Cohen, Myron S ^c   Mayaud, Philippe ^b  

^a KAMUZU CENTRAL HOSPITAL   (Malawi)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f MINISTRY OF HEALTH   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PLACEBO; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENITAL ULCER; HEADACHE; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY COLIC; MAJOR CLINICAL STUDY; MALAWI; MALE; MIXED INFECTION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPERM; TREATMENT OUTCOME; ULCER HEALING; UTERINE CERVIX; VIRUS LOAD; VOMITING;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALAWI; MALE; MEDICATION ADHERENCE; RECURRENCE; RNA, VIRAL; ULCER; VIRAL LOAD; YOUNG ADULT;

EID: 77958077166     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2009.041814     Document Type: Article

References (49)

1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3-17.
2. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52.
3. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 2006;20:73-83.
4. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-53.
5. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000;182:1090-6.
6. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. Aids 2002;16:2425-30.
7. Legoff J, Weiss HA, Gresenguet G, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. Aids 2007;21:1569-78.
8. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35:435-45.
9. World Health Organisation. Guidelines for the management of sexually transmitted infections; revised version. Geneva: WHO, 2003.
10. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004;11(Suppl 1):24A-35A.
11. Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 2004;11(Suppl 1):2A-23A.
12. Behets FM, Liomba G, Lule G, et al. Sexually transmitted diseases and human immunodeficiency virus control in Malawi: a field study of genital ulcer disease. J Infect Dis 1995;171:451-5.
13. Hoyo C, Hoffman I, Moser BK, et al. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. Sex Transm Dis 2005;32:231-7.
14. Paz-Bailey G, Rahman M, Chen C, et al. Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis 2005;41:1304-12.
15. Morse SA, Trees DL, Htun Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997;175:583-9.
16. Chen CY, Ballard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000;27:21-9.
17. National AIDS Commission. STI Service Provider's Handbook. 2003.
18. Chen CY, Chi KH, Alexander S, et al. The molecular diagnosis of lymphogranuloma venereum: evaluation of a real-time multiplex polymerase chain reaction test using rectal and urethral specimens. Sex Transm Dis 2007;34:451-5.
19. van Dyck E, Buve A, Weiss HA, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol 2004;42:2961-5.
20. LeGoff J, Mayaud P, Gresenguet G, et al. Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. J Clin Microbiol 2008;46:1914-18.
21. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.
22. World Health Organisation. Herpes simplex virus type 2: Programmatic and research priorities in developing countries. Report of a WHO/UNAIDS/LSHTM Workshop (London 14-16 February 2001). WHO/HIV-AIDS/2001.05. Geneva: WHO, 2001.
23. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55:1-94.
24. Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis 2009;200:216-26.
25. Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: A randomized, controlled trial. J Infect Dis 2009;200:1039-49.
26. Corey L, Bodsworth N, Mindel A, et al. An update on short-course episodic and prevention therapies for herpes genitalis. Herpes 2007;14(Suppl 1):5A-11A.
27. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007;370:2127-37.
28. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-6.
29. Chakraborty H, Sen PK, Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. Aids 2001;15:621-7.
30. Dyer JR, Kazembe P, Vernazza PL, et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998;177:1742-6.
31. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008;198:241-9.
32. Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. Aids 2007;21:589-98.
33. Kaul R, Pettengell C, Sheth PM, et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol 2008;77:32-40.
34. Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008;8:490-7.
35. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109-19.
36. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-9.
37. Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. Aids 2006;20:2305-13.
38. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. Aids 2009;23:461-9.
39. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008;49:77-83.
40. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-8.
41. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007;196:1500-8.
42. Zuckerman RA, Lucchetti A, Whittington WL, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. Aids 2009;23:479-83.
43. Vanpouille C, Lisco A, Margolis L. Acyclovir: a new use for an old drug. Curr Opin Infect Dis 2009.
44. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008;4:260-70.
45. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358:1560-71.
46. Celum C, Wald A, Lingappa JR. Twice-daily acyclovir to reduce HIV-1 transmission from HIV-1 / HSV-2 co-infected persons within HIV-1 serodiscordant couples: a randomized, double-blind, placebo-controlled trial. (Abstract WELBC 101). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa 2009.
47. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009;15:886-92.
48. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204:595-603.
49. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008;3:e2230.